Immunology

Drug company reports data on HIV research at international AIDS conference

Published in Gene Therapy Weekly, August 12th, 2004

The Immune Response Corporation (IMNR) announced that research results suggest its newest HIV product candidate, IR103, generated robust HIV-1 specific immune responses.

IR103 combines the company's patented HIV-1 immunogen with the immunostimulatory oligonucleotide adjuvant Amplivax. Results of two studies were presented at the XV International AIDS Conference in Bangkok, Thailand.

A preclinical study in which mice immunized subcutaneously with IR103 showed significantly enhanced production of a number of key markers of HIV-specific immune responses. These data demonstrate the potential to enhance both cell-mediated and humoral immunity, both of...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2004-08-12)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry